Description

Killer cell lectin-like receptor G1 (KLRG1) is the mouse homolog of the rat mast cell function-associated antigen (MAFA or 2F1-Ag).  KLRG1 is a type II membrane glycoprotein that was first identified on the surface of rat mast cell line RBL-2H3.  It is composed of a homodimer of glycosylated 30-38 kD subunits.  Mouse and human homologs of KLRG1 are expressed by subsets of NK cells and lymphokine-activated killer (LAK) cells but not mast cells.  KLRG1 is also expressed on subsets of CD8⁺ and CD4⁺ cells, including CD4⁺ and CD8⁺ effector/memory cells, potent regulatory CD4⁺ T cells.  KLRG1 may be involved in regulating NK cell homeostasis.  KLRG1 was found to recognize cadherins and thus inhibit immune responses by regulating the effector function and the developmental processes of NK and T cells.

Formulation

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Robbins SH, et al. 2002. J. Immunol. 168:2585. (WB)
2. Robbins SH, et al. 2003. J. Immunol. 170:5876. (FC)
3. McMahon CW, et al. 2002. J. Immunol. 169:1444. (FC)